Brief: Fusen Pharmaceutical Says Agomelatine Tablets Approved For Marketing In China By NMPA
08/06/2026 16:16
BRIEF-Fusen Pharmaceutical Says Agomelatine Tablets Approved For Marketing In China By NMPA June 8 (Reuters) - Fusen Pharmaceutical Co Ltd 1652.HK:
AGOMELATINE TABLETS APPROVED FOR MARKETING IN CHINA BY NMPA FOR DEPRESSION
Further company coverage: 1652.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fusen Pharmaceutical
See all newsBrief: Fusen Pharmaceutical Logs HY Loss Attributable RMB13.6 Million
Brief: Fusen Pharmaceutical Says Doxazosin Mesylate Extended-Release Tablets Approved For Marketing In China
Brief: Fusen Pharmaceutical Says Peramivir Injection First Neuraminidase Inhibitor Approved In China For Intravenous Influenza Treatment
Brief: Fusen Pharmaceutical Says Investors To Contribute RMB300 Mln For 34% Stake Subscription Of Henan Fusen Pharmaceutical
Brief: Fusen Pharmaceutical Says Piracetam Injection Approved For Marketing By NMPA